A Phase 1/2 interventional study of MOR03087 phase 1 dose escalation and MOR03087 in Multiple Myeloma, sponsored by MorphoSys AG. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-16.
Sponsored by MorphoSys AG (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Multiple Myeloma by Novartis — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Novartis.
Among the 42 studies in Multiple Myeloma by Novartis, this one is the 11th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2011, is one of 4 in phase 1/2, and was the 21st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 42 studies in Multiple Myeloma by Novartis is open now. The open studies under Multiple Myeloma, anywhere →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 15 · Phase 3 2 · Phase 4 5
First in 2000; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 43 across the 39 interventional studies, 1,496 across the 1 observational. Of the 38 that completed or were terminated, 14 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MorphoSys AG, one of the names counted as Novartis. Under that name alone:
MorphoSys AG is the lead sponsor of 11 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 42 studies in Multiple Myeloma by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with relapsed/refractory multiple myeloma in combination with standard therapy.
The study enrolled patients aged 18 years or older with relapsed or refractory multiple myeloma and Karnofsky performance status of 60% or higher. Patients were assigned to the different treatment regimens with MOR202 ranging between 0·01 mg/kg and 16 mg/kg in a 3 + 3 design. Dose-escalation and expansion was done either with MOR202 intravenous infusions alone (MOR202 q2w [twice a week] and q1w [weekly] groups) or in combination with dexamethasone (MOR202 with dexamethasone group), with dexamethasone plus pomalidomide (MOR202 with dexamethasone plus pomalidomide group) or plus lenalidomide (MOR202 with dexamethasone plus lenalidomide group). Primary endpoints were safety, MOR202 maximum tolerated dose (or recommended dose) and regimen, and immunogenicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
multiple myeloma defined as:
Parts A, B and C:
(i) Failure of at least 2 previous therapies which must have included an immunomodulatory agent and a proteasome inhibitor (either together or part of different therapies) (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma
Part D:
(i) At least 2 previous therapies including lenalidomide and a proteasome inhibitor (ii) All subjects must have documented progression during or within 60 days after their last prior therapy for multiple myeloma
Part E:
(i) Received at least one previous therapy (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: MOR03087 dose escalation; biweekly treatment Part B: MOR03087 dose escalation; weekly treatment Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment.
Drug: MOR03087 phase 1 dose escalation · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Lenalidomide
Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone. Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects. Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects. For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment.
Drug: MOR03087 · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Lenalidomide
Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle. In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.
MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087
1. as monotherapy 2. in combination with dexamethasone 3. in combination with pomalidomide + dexamethasone 4. in combination with lenalidomide + dexamethasone
Time frame: First cycle of treatment
Number of Participants Who Develop Anti-MOR03087 Antibodies
Number of participants who develop anti-MOR03087 antibodies, a measure of immunogenicity
Time frame: during treatment period, maximum 3 years after 1st dose
Overall Response Rate
number (#) of patients responding (# stringent complete response + # complete response + # very good partial response + # partial response)
Time frame: maximum 3 years after 1st dose
Time to Progression
Time to Progression (Kaplan Meier estimate)
Time frame: patients were observed for up to 36 months
Progression-free Survival
Progression-free survival (Kaplan Meier estimates)
Time frame: patients were observed up to 36 months
Duration of Response
Duration of response (Kaplan Meier estimates)
Time frame: patients were observed up to 36 months
Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202
PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups
Time frame: up to 7 days after last MOR202 dose
Pharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR202
PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups
Time frame: 56 days
| Milestone | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| Started | 31 | 4 | 18 | 21 | 17 |
| Completed | 31 | 4 | 18 | 21 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
1. as monotherapy 2. in combination with dexamethasone 3. in combination with pomalidomide + dexamethasone 4. in combination with lenalidomide + dexamethasone
| mg/kg | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087 | 16 | 16 | 16 | 16 | 16 |
Number of participants who develop anti-MOR03087 antibodies, a measure of immunogenicity
| Participants | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| Number of Participants Who Develop Anti-MOR03087 Antibodies | 0 | 0 | 0 | 0 | 0 |
number (#) of patients responding (# stringent complete response + # complete response + # very good partial response + # partial response)
| Participants | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| Overall Response Rate | 0 | 0 | 5 | 10 | 11 |
Time to Progression (Kaplan Meier estimate)
| months | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| Time to Progression | 1.1 (1.0 to 1.4) | 2.1 (0.7 to NA) | 8.4 (1.4 to 11.1) | 15.9 (4.1 to 25.8) | 33.2 (5.1 to NA) |
Progression-free survival (Kaplan Meier estimates)
| months | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| Progression-free Survival | 1.1 (1.0 to 1.4) | 2.1 (0.7 to NA) | 8.4 (1.4 to 11.1) | 15.9 (3.0 to 22.1) | 26.7 (5.1 to NA) |
Duration of response (Kaplan Meier estimates)
| months | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|
| Duration of Response | 16.7 (1.9 to NA) | 21.2 (9.2 to NA) | 32.2 (4.2 to NA) |
PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups
| µg/mL | 4 mg/kg QW | 8 mg/kg QW | 16 mg/kg QW |
|---|---|---|---|
| Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202 | 137.86 ± 79.43 | 311.67 ± 118.33 | 681.53 ± 226.69 |
PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups
| mg*days/L | 4 mg/kg QW | 8 mg/kg QW | 16 mg/kg QW |
|---|---|---|---|
| Pharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR202 | 3307.57 ± 2332.07 | 7970.15 ± 4289.21 | 18178.57 ± 8414.44 |
Collected over during the entire period of trial drug application and beyond until end of study visit/up to 30 days after last administration of study drug. Patients stayed on study drug up to 3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: MOR03087 Biweekly Dose Escalation | 2/31 (6.5%) | 13/31 (41.9%) | 31/31 (100%) |
| Part B: MOR03087 Weekly Dose Escalation | 0/4 (0%) | 4/4 (100%) | 4/4 (100%) |
| Part C: MOR03087 Plus Dexamethasone | 0/18 (0%) | 7/18 (38.9%) | 18/18 (100%) |
| Part D: MOR03087 Plus Pomalidomide + Dexamethasone | 1/21 (4.8%) | 20/21 (95.2%) | 21/21 (100%) |
| Part E: MOR03087 Plus Lenalidomide + Dexamethasone | 4/17 (23.5%) | 14/17 (82.4%) | 17/17 (100%) |
| Event | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| Infusion-related reactionInjury, poisoning and procedural complications | 4/31 | 4/4 | 0/18 | 1/21 | 0/17 |
| PneumoniaInfections and infestations | 1/31 | 0/4 | 1/18 | 6/21 | 1/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/31 | 1/4 | 0/18 | 1/21 | 0/17 |
| Atrial FibrillationCardiac disorders | 0/31 | 1/4 | 0/18 | 1/21 | 0/17 |
| PericarditisCardiac disorders | 0/31 | 1/4 | 0/18 | 0/21 | 0/17 |
| InfectionInfections and infestations | 0/31 | 1/4 | 0/18 | 0/21 | 0/17 |
| Respiratory tract infectionInfections and infestations | 0/31 | 0/4 | 0/18 | 3/21 | 0/17 |
| Plasma Cell MyelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/31 | 0/4 | 0/18 | 0/21 | 0/17 |
| BronchitisInfections and infestations | 0/31 | 0/4 | 2/18 | 0/21 | 0/17 |
| PyrexiaGeneral disorders | 0/31 | 0/4 | 1/18 | 2/21 | 0/17 |
| Event | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone |
|---|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 8/31 | 4/4 | 8/18 | 17/21 | 15/17 |
| NeutropeniaBlood and lymphatic system disorders | 4/31 | 3/4 | 8/18 | 19/21 | 12/17 |
| LymphopeniaBlood and lymphatic system disorders | 5/31 | 2/4 | 8/18 | 14/21 | 13/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/31 | 1/4 | 6/18 | 14/21 | 11/17 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 16/31 | 2/4 | 12/18 | 9/21 | 3/17 |
| ConstipationGastrointestinal disorders | 4/31 | 0/4 | 0/18 | 5/21 | 11/17 |
| DiarrheaGastrointestinal disorders | 7/31 | 1/4 | 4/18 | 11/21 | 10/17 |
| FatigueGeneral disorders | 11/31 | 0/4 | 6/18 | 12/21 | 6/17 |
| Muscle spasmMusculoskeletal and connective tissue disorders | 3/31 | 0/4 | 2/18 | 5/21 | 9/17 |
| AnaemiaBlood and lymphatic system disorders | 13/31 | 1/4 | 7/18 | 11/21 | 6/17 |
| Age, Categorical(Participants) | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 1 | 7 | 10 | 8 | 34 |
| >=65 years | 23 | 3 | 11 | 11 | 9 | 57 |
| Sex: Female, Male(Participants) | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 0 | 8 | 8 | 5 | 33 |
| Male | 19 | 4 | 10 | 13 | 12 | 58 |
| Race (NIH/OMB)(Participants) | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 31 | 4 | 18 | 21 | 17 | 91 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part A: MOR03087 Biweekly Dose Escalation | Part B: MOR03087 Weekly Dose Escalation | Part C: MOR03087 Plus Dexamethasone | Part D: MOR03087 Plus Pomalidomide + Dexamethasone | Part E: MOR03087 Plus Lenalidomide + Dexamethasone | Total |
|---|---|---|---|---|---|---|
| Austria | 0 | 0 | 3 | 1 | 0 | 4 |
| Germany | 31 | 4 | 15 | 20 | 17 | 87 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2011 to primary completion in Aug 2020, 109 months.
Results were first posted in Oct 2021, 1 year 2 months after primary completion.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 109 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Felzartamab